Investing News Network on MSN2d
Bird Flu Vaccine Stocks: 8 Companies Developing H5N1 Vaccines
Life science companies developing bird flu vaccines are gaining attention as the avian influenza subtype H5N1 becomes an ...
pharmaphorum26d
Preventing the next pandemic: Supporting early-stage R&D
The biotech is partnered with GSK to provide a monoclonal antibody (mAb) as a treatment for COVID-19. A spokesperson for the biotech told pharmaphorum, “The COVID-19 pandemic highlighted the ...
pharmaphorum8d
AstraZeneca beats expectations in Q2, while GSK struggles during pandemic
AstraZeneca has beaten analysts’ expectations in its second quarter results, outshining its UK counterpart GlaxoSmithKline, which has been hit by disruption caused by the COVID-19 pandemic.
The Lancet2d
An overview of influenza H5 vaccines
Pandemic influenza remains a significant global health threat, as signalled by the circulation and cross-species transmission of avian influenza A(H5N1) viruses from the clade 2.3.4.4b, including ...
US FDA approves GSK's combo meningococcal vaccine
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal infection for use in people aged 10 through 25 years, the company said on ...
Canada buys 500,000 doses of H5N1 avian influenza vaccine for those most at risk
The Public Health Agency of Canada said Wednesday it's purchased 500,000 doses of a human vaccine to protect against avian ...
MedCity News1mon
A Snapshot of Five Contenders to Combat Infectious Diseases in the Post-Pandemic Landscape
The Covid-19 pandemic changed the business case for vaccine ... presents a critical new target for vaccine development. GSK paid $431.4 million to acquire CureVac’s clinical-stage mRNA vaccines ...